5Sauder DN.Immunomodulatory and pharmacologic prooerties of imiquimod.J Am Acad Dermatol 2000,43(7)(1 Pt 2):S6-11.Review 被引量：1
6Wager TL,Ahonen CL,Couture AM,et al.Modulation of TH1 and TH2 cytokine production with the immune response modifiers,R-848 and imiquimod.Cell Immunol 1999,191(1):10-19 被引量：1
7Garland SM,Sellors JW,Wikstorom A,et al.Imiquimod 5%cream is a safe and effective self-applied treatment for anogenital warts-results of an open-label,multicentre Phase Ⅲ B Trial.Int SJTD AIDS 2001,12(11):722-729 被引量：1
5Beutner KR,Spruance SL,Hougham A J,et al.Treatment of genital warts with an immune-response modifier (imiquimod).J Am Acad Dermatol,1998,38:230-239. 被引量：1
6Moore RA,Edwards JE,Hopwood J,et al.Imiquimod for the treatment of genital warts:a quantitative systematic review.BMC Infect Dis,2001,1:3. 被引量：1
7Syed TA, Ahmadpour OA, Ahmad SA, et al. Management of toenail onychomycosis with 2% butenafine and 20% urea cretan: a placebo-controlled, double-blind study. J Dermatol, 1998 , 25: 648-652. 被引量：1
8Perry CM, Lamb HM. Topical imiquimod: a review of its use in genital warts. Drugs, 1999 , 58: 375-390. 被引量：1
9Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol, 1998, 134: 25-30. 被引量：1
10Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol, 1998, 38(2 Pt 1 ): 230-239. 被引量：1
4Xiao-Li Yue,Xiang-Dong Gong,Jing Li,Ya-Jie Wang,Heng Gu.Gonorrhea in China, 2018[J].International Journal of Dermatology and Venereology,2019,2(2):65-69. 被引量：1
